Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

The deal struck with Helsinn Group is the latest evidence of the new opportunities for IP monetisation provided by hub-and-spokes life sciences companies

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

12 Apr 2021

@IAM_Alerts Six takeaways from the $1.8 billion settlement between LG Energy Solutions and SK Innovation https://t.co/DA8pliNsx3 https://t.co/8WxEHe1UJX Read more

11 Apr 2021

@IAM_Alerts We are hiring ... Check out this job at Law Business Research: Deputy Editor https://t.co/7MZFKDmAPV Read more

11 Apr 2021

@IAM_Alerts The IAM Sunday Supplement is now out, including: Aon’s $400m IP fund; Nokia seals major Lenovo deal; LG touts smart… https://t.co/VYFYqmqhqb Read more

10 Apr 2021

@IAM_Alerts RT @IAM_Alerts: In a split Senate, the fact that @ThomTillis, the ranking Republican member of the Judiciary Committee’s IP sub-committee,… Read more

Find an expert

Wenwen Wang

Partner

Guangzhou, China

Advance China IP Law Office

View full biography

Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

Returning user?

Want to read more?

Adam Houldsworth

TAGS

Twitter

Find an expert